MP15-13 A PHASE I TRIAL FOR THE USE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) IN THE TREATMENT OF BCG-REFRACTORY NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Guarionex DeCastro ◽  
Wilson Sui ◽  
Jamie Pak ◽  
Cory Abate-Shen ◽  
Shing Lee ◽  
...  
Keyword(s):  
Phase I ◽  
Urothelial Carcinoma ◽  
Phase I Trial ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive ◽  
Gemcitabine And Cisplatin

scholarly journals Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience

2014 ◽  
Vol 8 (3-4) ◽  
pp. 287 ◽  
Author(s):  
Faraj El-Gehani ◽  
Scott North ◽  
Sunita Ghosh ◽  
Peter Venner
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Urothelial Carcinoma ◽  
Clinical Stage ◽  
Retrospective Chart Review ◽  
Cancer Specific Survival ◽  
Risk Of Death ◽  
Lower Stage ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive ◽  
Gemcitabine And Cisplatin

Introduction: Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy (RC) for muscle invasive urothelial carcinoma of the bladder improves survival. This study was undertaken to determine the rate of neoadjuvant gemcitabine and cisplatin use prior to RC and to assess its effect on the pathologic response rates and cancer-specific survival (CSS) and overall survival (OS).Methods: This retrospective chart review examined all patients having a RC between January 1, 2007 and June 30, 2011. We collected patient demographics, pre-treatment clinical stage, type of chemotherapy, post-RC pathologic data and survival data.Results: A total of 251 RC were performed of which 160 were for stage cT2-T4 urothelial carcinoma of the bladder. Of the 160 patients, 91 (57%) received neoadjuvant gemcitabine and cisplatin (GC) and 69 (43%) went straight to RC. Patients receiving neoadjuvant GC had a greater chance of achieving a pathologically lower stage compared to the untreated population: pT0 at 21% vs. 3%; non-invasive cancer at 37% vs. 10%; and organ-confined cancer at 60% vs. 33% (p < 0.001). Survival correlated with pathological stage: ≤pT3a patients had a median OS and CSS of 48.8 and 51.2 months compared to an OS and a CSS in ≥pT3b patients of 21.8 and 28.1 months, respectively (p < 0.0001).Conclusions: Neoadjuvant chemotherapy for urothelial carcinoma of the bladder is more frequently administered at our institution compared to the published literature. We have found that neoadjuvant chemotherapy increases the rate of down-staging, which is associated with a reduced the risk of death from urothelial carcinoma of the bladder.

MP65-11 MUCIN 16 IS A MUTATIONAL HOTSPOT FOR NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Sumeet Syan-Bhanvadia ◽  
Christopher Duymich ◽  
Yong June Kim ◽  
Jessica Charlet ◽  
Hung-Yoon Yoon ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

scholarly journals Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans

Biomedicines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1472
Author(s):  
Maria Malvina Tsamouri ◽  
Thomas M. Steele ◽  
Maria Mudryj ◽  
Michael S. Kent ◽  
Paramita M. Ghosh
Keyword(s):  
Urothelial Carcinoma ◽  
Human Cancer ◽  
Clinical Signs ◽  
Common Type ◽  
Diagnostic Biomarkers ◽  
Naturally Occurring ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive ◽  
Cancer Cell Signaling

Muscle-invasive urothelial carcinoma (MIUC) is the most common type of bladder malignancy in humans, but also in dogs that represent a naturally occurring model for this disease. Dogs are immunocompetent animals that share risk factors, pathophysiological features, clinical signs and response to chemotherapeutics with human cancer patients. This review summarizes the fundamental pathways for canine MIUC initiation, progression, and metastasis, emerging therapeutic targets and mechanisms of drug resistance, and proposes new opportunities for potential prognostic and diagnostic biomarkers and therapeutics. Identifying similarities and differences between cancer signaling in dogs and humans is of utmost importance for the efficient translation of in vitro research to successful clinical trials for both species.

scholarly journals Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system

2018 ◽  
Vol 12 (8) ◽  
Author(s):  
Adam Kinnaird ◽  
Peter Dromparis ◽  
Howard Evans
Keyword(s):  
Urothelial Carcinoma ◽  
Healthcare System ◽  
Bladder Tumour ◽  
Muscularis Propria ◽  
High Grade ◽  
Recurrence Rates ◽  
Repeat Resection ◽  
Resource Limited ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

Introduction: Non-muscle-invasive bladder cancer is the most expensive malignancy to treat. Current Canadian guidelines recommend repeat transurethral resection of bladder tumour (TURBT) within six weeks after initial resection of T1 high-grade (T1HG) urothelial carcinoma, prior to initiation of intravesical bacillus Calmette- Guerin treatment. This is a burden on operating room usage and adds further cost and risk of complications. Internationally, major cancer centres report significant rates of recurrence and upstaging on repeat resection, however, minimal Canadian data is available. We aimed to determine the rate of recurrence and upstaging in a resource-limited, Canadian healthcare system.Methods: A retrospective review of patients receiving TURBT between November 2009 and November 2014 was performed. Patients were included if they had all three of the following: a pathological diagnosis of T1HG, adequate muscularis propria present in the specimen, and a repeat resection.Results: We reviewed 3166 patients who underwent TURBT and found 173 to meet our inclusion criteria. The overall recurrence and upstaging rates were 57.2% and 9.2%, respectively. Tumour recurrence and upstaging occurred more often in patients who had repeat resection after 12‒24 weeks compared to those patients whose repeat resection occurred within 12 weeks.Conclusions: Although recurrence rates are similar, we have found upstaging rates to be three- to four-fold lower than those previously reported. Despite this, one in 10 patients will be upstaged, justifying use of this resource within our healthcare system. Finally, timely repeat resection, within 12 weeks appears to be associated with preventing disease progression.

Sign in / Sign up

Export Citation Format

Share Document